Baird Medical Showcases Cutting-Edge MWA Innovations at NASOIE 2025
Baird Medical (NASDAQ: BDMD), a medical device company specializing in AI-powered surgical robotics and microwave ablation (MWA) technology, showcased its innovations at the 2025 North American Society of Interventional Endocrinologists (NASOIE) Annual Meeting in Lehi, Utah.
The company's booth attracted significant physician interest, featuring hands-on thyroid phantom demonstrations that highlighted their MWA technology's precision, safety, and efficiency. Company experts engaged with attendees in detailed discussions about clinical applications and practical insights regarding MWA in thyroid care.
The event, which focuses on advancing minimally invasive treatments for thyroid and parathyroid disorders, provided Baird Medical an opportunity to reinforce its position in next-generation thyroid ablation therapies. The company plans to utilize insights gained from NASOIE 2025 to further enhance its MWA technology for thyroid treatment solutions.
Baird Medical (NASDAQ: BDMD), un'azienda di dispositivi medici specializzata in robotica chirurgica alimentata da intelligenza artificiale e tecnologia di ablazione a microonde (MWA), ha presentato le sue innovazioni durante il Meeting Annuale della North American Society of Interventional Endocrinologists (NASOIE) 2025 a Lehi, Utah.
Lo stand dell'azienda ha attirato un notevole interesse da parte dei medici, presentando dimostrazioni pratiche su fantocci tiroidei che hanno messo in evidenza la precisione, la sicurezza e l'efficienza della loro tecnologia MWA. Gli esperti dell'azienda hanno interagito con i partecipanti in discussioni dettagliate sulle applicazioni cliniche e sulle intuizioni pratiche riguardanti la MWA nella cura della tiroide.
L'evento, che si concentra sul progresso dei trattamenti minimamente invasivi per i disturbi tiroidei e paratiroidei, ha fornito a Baird Medical l'opportunità di rafforzare la propria posizione nelle terapie di ablazione tiroidea di nuova generazione. L'azienda prevede di utilizzare le intuizioni ottenute dal NASOIE 2025 per migliorare ulteriormente la propria tecnologia MWA per le soluzioni di trattamento della tiroide.
Baird Medical (NASDAQ: BDMD), una empresa de dispositivos médicos especializada en robótica quirúrgica impulsada por inteligencia artificial y tecnología de ablación por microondas (MWA), presentó sus innovaciones en la Reunión Anual de la North American Society of Interventional Endocrinologists (NASOIE) 2025 en Lehi, Utah.
El stand de la empresa atrajo un gran interés por parte de los médicos, con demostraciones prácticas de fantasmas tiroideos que destacaron la precisión, seguridad y eficiencia de su tecnología MWA. Los expertos de la empresa interactuaron con los asistentes en discusiones detalladas sobre aplicaciones clínicas y perspectivas prácticas relacionadas con la MWA en el cuidado de la tiroides.
El evento, que se centra en avanzar en tratamientos mínimamente invasivos para trastornos de la tiroides y paratiroides, brindó a Baird Medical la oportunidad de reforzar su posición en las terapias de ablación tiroidea de próxima generación. La empresa planea utilizar las ideas obtenidas del NASOIE 2025 para mejorar aún más su tecnología MWA para soluciones de tratamiento de la tiroides.
Baird Medical (NASDAQ: BDMD)는 인공지능 기반의 외과 로봇 및 마이크로웨이브 절제(MWA) 기술을 전문으로 하는 의료 기기 회사로, 2025년 북미 개입 내분비학회(NASOIE) 연례 회의에서 혁신을 선보였습니다. 유타주 레히에서 개최되었습니다.
회사의 부스는 의사들의 많은 관심을 끌었으며, MWA 기술의 정밀도, 안전성 및 효율성을 강조하는 갑상선 모형 시연이 포함되었습니다. 회사의 전문가들은 참석자들과 MWA의 갑상선 치료에 관한 임상 응용 및 실용적인 통찰에 대해 상세한 논의를 진행했습니다.
갑상선 및 부갑상선 질환에 대한 최소 침습 치료를 발전시키는 데 중점을 둔 이 행사는 Baird Medical이 차세대 갑상선 절제 요법에서의 입지를 강화할 수 있는 기회를 제공했습니다. 회사는 NASOIE 2025에서 얻은 통찰력을 활용하여 갑상선 치료 솔루션을 위한 MWA 기술을 더욱 향상시킬 계획입니다.
Baird Medical (NASDAQ: BDMD), une entreprise de dispositifs médicaux spécialisée dans la robotique chirurgicale alimentée par l'intelligence artificielle et la technologie d'ablation par micro-ondes (MWA), a présenté ses innovations lors de la Réunion Annuelle de la North American Society of Interventional Endocrinologists (NASOIE) 2025 à Lehi, Utah.
Le stand de l'entreprise a suscité un intérêt significatif de la part des médecins, avec des démonstrations pratiques sur des fantômes thyroïdiens qui ont mis en avant la précision, la sécurité et l'efficacité de leur technologie MWA. Des experts de l'entreprise ont engagé des discussions détaillées avec les participants sur les applications cliniques et les perspectives pratiques concernant la MWA dans les soins de la thyroïde.
L'événement, qui se concentre sur l'avancement des traitements peu invasifs pour les troubles de la thyroïde et des parathyroïdes, a offert à Baird Medical l'opportunité de renforcer sa position dans les thérapies d'ablation thyroïdienne de nouvelle génération. L'entreprise prévoit d'utiliser les informations recueillies lors du NASOIE 2025 pour améliorer encore sa technologie MWA pour les solutions de traitement de la thyroïde.
Baird Medical (NASDAQ: BDMD), ein Unternehmen für medizinische Geräte, das auf KI-gestützte chirurgische Robotik und Mikrowellenablation (MWA) spezialisiert ist, stellte seine Innovationen auf dem Jahresmeeting der North American Society of Interventional Endocrinologists (NASOIE) 2025 in Lehi, Utah, vor.
Der Stand des Unternehmens zog erhebliches Interesse von Ärzten an und bot praktische Demonstrationen von Schilddrüsenphantomen, die die Präzision, Sicherheit und Effizienz ihrer MWA-Technologie hervorhoben. Unternehmensspezialisten führten mit den Teilnehmern detaillierte Gespräche über klinische Anwendungen und praktische Einblicke zur MWA in der Schilddrüsenversorgung.
Die Veranstaltung, die sich auf die Förderung minimalinvasiver Behandlungen von Schilddrüsen- und Nebenschilddrüsenerkrankungen konzentriert, bot Baird Medical die Möglichkeit, seine Position in der nächsten Generation von Schilddrüsenablationstherapien zu stärken. Das Unternehmen plant, die Erkenntnisse aus dem NASOIE 2025 zu nutzen, um seine MWA-Technologie für Schilddrüsenbehandlungslösungen weiter zu verbessern.
- Strong physician engagement at industry conference
- Successful demonstration of MWA technology capabilities
- Reinforced market position in thyroid ablation therapies
- None.
As a premier gathering for experts in interventional endocrinology, NASOIE serves as a platform for advancing minimally invasive treatments for thyroid and parathyroid disorders. The event convenes top-tier clinicians and researchers to explore the latest breakthroughs in treating thyroid nodules and cancer recurrences.
Baird Medical's presence at NASOIE 2025 drew strong engagement, with numerous physicians visiting the booth to explore the latest advancements in MWA technology. Attendees participated in hands-on thyroid phantom demonstrations, experiencing firsthand the precision, safety, and efficiency of Baird's technology. The Company's experts engaged in in-depth discussions, addressing key clinical considerations and providing practical insights into MWA's role in thyroid care. Through these interactions, Baird Medical further solidified its leadership in next-generation thyroid ablation therapies, enhancing industry awareness, and reinforcing its commitment to innovation in minimally invasive treatment solutions.
Baird Medical remains dedicated to advancing minimally invasive thyroid treatments by working closely with medical experts and industry leaders. The insights gained from NASOIE 2025 will help further refine the Company's MWA technology, ensuring it meets the evolving needs of thyroid care. Through continued research, education, and collaboration, Baird Medical is committed to improving treatment options for patients with thyroid nodules and related conditions worldwide.
About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.
These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.
Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-showcases-cutting-edge-mwa-innovations-at-nasoie-2025-302389649.html
SOURCE BDMD
FAQ
What did Baird Medical (BDMD) showcase at NASOIE 2025?
How did physicians respond to Baird Medical's (BDMD) presentation at NASOIE 2025?
What is the significance of NASOIE 2025 for Baird Medical (BDMD)?
How will Baird Medical (BDMD) utilize the feedback from NASOIE 2025?
